Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies — Jenny Lee (2018) | RDL Network
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
Article 2018 en
Authors
JL
Jenny Lee
GL
Georgina V. Long
AM
Alexander M. Menzies
Abstract
1 min read
The results demonstrate that ctDNA profiles can accurately differentiate pseudoprogression from true progression of disease in patients with melanoma treated with PD-1 antibodies. Results of this blood test performed at regular intervals during systemic treatment reflect tumor biology and have potential as a powerful biomarker to predict long-term response and survival.
Elin S. Gray, Helen Rizos, Anna Reid, Suzanah C. Boyd, Michelle R. Pereira, Johnny Lo, Varsha Tembe, James Freeman, Jenny Lee, Richard A Scolyer, Kelvin Shenq Woei Siew, Chris Lomma, Adam Cooper, Muhammad A. Khattak, Tarek Meniawy, Georgina V. Long, Matteo S. Carlino, Michael Millward, Mel Ziman
Mark A. Dawson, Anthony T. Papenfuss, Mark Shackleton, Rodney J. Hicks, Grant A. McArthur, Shahneen Sandhu, Sarah‐Jane Dawson, Stephen Q. Wong, Jeanette Raleigh, Jason Callahan, Ismael A. Vergara, Sarah Ftouni, Athena Hatzimihalis, Andrew J. Colebatch, Jason Li, Timothy Semple, Kenneth Doig, Christopher Mintoff, Devbarna Sinha, Paul Yeh, Maria João Silva, Kathryn Alsop,
Russell J. Diefenbach, Jenny Lee, Dario Strbenac, Jean Yang, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Andrew J. Spillane, Jonathan R. Stretch, Robyn P.M. Saw, John F. Thompson, Sydney Ch’ng, Richard A Scolyer, Richard Kefford, Helen Rizos
Tuba N. Gide, Inês Pires da Silva, Camelia Quek, Tasnia Ahmed, Alexander M. Menzies, Matteo S. Carlino, Robyn P.M. Saw, John F. Thompson, Marcel Batten, Georgina V. Long, Richard A Scolyer, James S. Wilmott
Discussion(0)
No comments yet. Be the first to comment.